ESMO 2017—my personal highlights
暂无分享,去创建一个
[1] L. Einhorn,et al. 1297ORandomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) , 2017 .
[2] A. Zubel,et al. 994OEquivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study , 2017 .
[3] L. Sequist,et al. LBA49Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC , 2017 .
[4] Y. Ohe,et al. LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA , 2017 .
[5] D. Planchard,et al. LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC , 2017 .
[6] Peter Schmid,et al. LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 , 2017 .
[7] H. Groen,et al. Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) , 2017 .
[8] E. Devin,et al. 1273OResults of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC) , 2017 .
[9] M. Piccart,et al. 150O_PRNot all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy , 2017 .
[10] M. Goetz,et al. 236O_PRMONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer , 2017 .
[11] M. Shipp,et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. , 2017, Blood.
[12] A. LaCasce,et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. , 2017, Blood.